Robert Perez Net Worth

The estimated Net Worth of Robert J Perez is at least $399 mil dollars as of 20 April 2015. Mr. Perez owns over 5,000 units of Vir Biotechnology Inc stock worth over $39,150 and over the last 16 years he sold VIR stock worth over $0. In addition, he makes $359,667 as Independent Director at Vir Biotechnology Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Perez VIR stock SEC Form 4 insiders trading

Robert has made over 1 trades of the Vir Biotechnology Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of VIR stock worth $80,000 on 20 April 2015.

The largest trade he's ever made was buying 5,000 units of Vir Biotechnology Inc stock on 20 April 2015 worth over $80,000. On average, Robert trades about 109 units every 0 days since 2009. As of 20 April 2015 he still owns at least 5,000 units of Vir Biotechnology Inc stock.

You can see the complete history of Mr. Perez stock trades at the bottom of the page.

Robert Perez biography

Robert J. Perez serves as Independent Director of the Company. Mr. Perez has been an Operating Partner at General Atlantic, a global growth equity firm, since January 2019, the Executive Chairman and member of the board of directors of Akili Interactive Labs, Inc. since 2017, the founder and Chairman of Life Science Cares, a non-profit organization, since 2016, and was the founder and Managing Partner at Vineyard Sound Advisors, LLC, a biopharmaceutical consulting firm, from March 2015 to December 2018. He previously served as Chief Executive Officer of Cubist Pharmaceuticals, Inc. (“Cubist”), a public pharmaceutical company, from January 1, 2015 until Cubist was acquired by Merck later that month. Mr. Perez joined Cubist in 2003 as Senior Vice President, Sales and Marketing, and served as Executive Vice President and Chief Operating Officer from 2007 to 2012 and President and Chief Operating Officer from 2012 to December 2014. Prior to joining Cubist, Mr. Perez held positions of increasing responsibility at Biogen from 1995 to 2003, most recently as Vice President of Biogen’s CNS business unit. Mr. Perez previously held various sales and marketing positions at Zeneca Pharmaceuticals. Mr. Perez has been a director of AMAG Pharmaceuticals, Inc., a public pharmaceutical company, since January 2009, Zafgen, Inc. a public biopharmaceutical company, since September 2015, and Spark Therapeutics, Inc., a public gene therapy company, since January 2018.

What is the salary of Robert Perez?

As the Independent Director of Vir Biotechnology Inc, the total compensation of Robert Perez at Vir Biotechnology Inc is $359,667. There are 13 executives at Vir Biotechnology Inc getting paid more, with George Scangos having the highest compensation of $3,944,610.

How old is Robert Perez?

Robert Perez is 55, he's been the Independent Director of Vir Biotechnology Inc since 2017. There are 14 older and 9 younger executives at Vir Biotechnology Inc. The oldest executive at Vir Biotechnology Inc is Phillip Sharp, 75, who is the Independent Director.

What's Robert Perez's mailing address?

Robert's mailing address filed with the SEC is C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO, CA, 94158.

Insiders trading at Vir Biotechnology Inc

Over the last 5 years, insiders at Vir Biotechnology Inc have traded over $197,171,926 worth of Vir Biotechnology Inc stock and bought 6,960,011 units worth $139,246,875 . The most active insiders traders include Norbert W Bischofberger, Endurance (Cayman) Ltd Sb I... y Kristina Burow. On average, Vir Biotechnology Inc executives and independent directors trade stock every 7 days with the average trade being worth of $478,115. The most recent stock trade was executed by Janet Napolitano on 9 September 2024, trading 12,190 units of VIR stock currently worth $95,082.

What does Vir Biotechnology Inc do?

vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. the company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.

Complete history of Mr. Perez stock trades at AMAG Pharmaceuticals, Cidara Therapeutics Inc, Zafgen, Unum Therapeutics y Vir Biotechnology Inc

Vir Biotechnology Inc executives and stock owners

Vir Biotechnology Inc executives and other stock owners filed with the SEC include:

• George Scangos,
  President, Chief Executive Officer, Director
• Howard Horn,
  Chief Financial Officer, Secretary
• Herbert Virgin,
  Executive Vice President of Research and Chief Scientific Officer
• Vicki Sato,
  Independent Chairman of the Board
• Dr. Herbert W. Virgin IV, M.D., Ph.D.,
  Exec. VP of Research & Chief Scientific Officer
• Dr. Herbert W. Virgin IV,
  Exec. VP of Research & Chief Scientific Officer
• Dr. George A. Scangos Ph.D.,
  Pres, CEO & Director
• Dr. Ann M. Hanly Ph.D.,
  Exec. VP & Chief Technology Officer
• Phil Pang,
  Chief Medical Officer
• Dr. George A. Scangos,
  Pres, CEO & Director
• Dr. Phillip Pang M.D., Ph.D.,
  Exec. VP & Chief Medical Officer
• Steven J. Rice,
  Chief Admin. Officer
• Saira Ramasastry,
  Independent Director
• Robert Perez,
  Independent Director
• Phillip Sharp,
  Independent Director
• Dr. Klaus Frueh,
  Co-Founder & Scientific Advisor
• Robert More,
  Independent Director
• Dipchand Nishar,
  Independent Director
• Robert Nelsen,
  Independent Director
• Elliott Sigal,
  Independent Director
• Janet Napolitano,
  Director
• Michael Kamarck,
  Chief Technology Officer
• Jay Parrish,
  Chief Business Officer
• Johanna Friedl-Naderer,
  Exec. VP & COO
• Irene Pleasure J.D., Ph.D.,
  Sr. VP & Gen. Counsel
• Heather Rowe Armstrong,
  VP of Investor Relations
• Dr. Aine M. Hanly Ph.D.,
  Chief Technology Officer
• Dr. Louis J. Picker M.D.,
  Co-Founder & Scientific Advisor
• Dr. Klaus Frueh Ph.D.,
  Co-Founder & Scientific Advisor
• Dr. Neera Dahiya Ravindran M.D., MBA,
  VP and Head of Investor Relations & Strategic Communications
• Dr. Louis J. Picker,
  Co-Founder & Scientific Advisor
• Dr. Lawrence Corey,
  Co-Founder & Scientific Advisor
• Permanent Fund Corp Alaska,
  
• & Melinda Gates Foundation ...,
  
• Johanna Friedl Naderer,
  EVP & Chief Operating Officer
• Steven J. Rice,
  Chief Administrative Officer
• Venture Partners Ix, Llcarc...,
  
• Endurance (Cayman) Ltd Sb I...,
  
• Dhabi Investment Authority ...,
  
• Holdings (Private) Ltd Full...,
  
• Program Ii (Co Invest Holdi...,
  
• Mark Eisner,
  EVP and Chief Medical Officer
• Klaus Frueh,
  Director
• Venture Partners Ix, Llcarc...,
  
• Kristina Burow,
  Director
• Jeffrey S. Hatfield,
  Director
• Norbert W Bischofberger,
  Director
• Ramy Farid,
  Director
• Sung Lee,
  EVP & Chief Financial Officer
• Ann M. Hanly,
  EVP & Chief Technology Officer
• Backer Marianne De,
  Chief Executive Officer